News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Leaves Door Ajar To Pfizer Inc. (PFE), Despite Hurdles



5/14/2014 4:51:29 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

May 14, 2014 -- AstraZeneca's boss said on Wednesday he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's operations into the U.S. company's new three-unit model were addressed.

Chief Executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca's board to negotiate if terms were sufficiently attractive in a sweetened offer.

"Every shareholder says at the right level with the right offer you should consider it - that is very clear. But there is nobody who has told us a specific price at which we should engage," he told Reuters in an interview.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Financial Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES